Edesa Biotech
EDSA
23 hedge funds and large institutions have $7.1M invested in Edesa Biotech in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
66% more capital invested
Capital invested by funds: $4.28M → $7.1M (+$2.82M)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
15% more funds holding
Funds holding: 20 → 23 (+3)
10.86% more ownership
Funds ownership: 30.02% → 40.88% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.59M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.6K |
| 3 |
Renaissance Technologies
New York
|
+$57.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$40K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$21.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.46K |
| 3 |
Morgan Stanley
New York
|
-$1.19K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$59 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$7 |
EDSA Hedge Fund Activity: Q3 2025 in Review
23 of the 7,646 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q3 2025, worth a combined $7.1M — up 66% from $4.28M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EDSA positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $1.59M. The largest seller was Citadel Advisors, cutting an estimated $21.9K.
- 23 institutional investors held Edesa Biotech (EDSA) as of Q3 2025, up from 20 in Q2 2025.
- Funds reported $7.1M of Edesa Biotech stock for Q3 2025, up 66% quarter-over-quarter.
- 5 funds opened new Edesa Biotech positions in Q3 2025 and 2 closed out, a net change of +3 holders.
- The largest Edesa Biotech buyer in Q3 2025 was Stonepine Capital Management, an estimated $1.59M added.
- The largest Edesa Biotech seller in Q3 2025 was Citadel Advisors, an estimated $21.9K sold.
Based on aggregated 13F filings for Q3 2025.